Last updated: February 24, 2026
What is NDC 62856-0583?
NDC 62856-0583 refers to Rivalta Bayer (rivaroxaban), a novel oral anticoagulant marketed primarily for thromboembolic conditions. The drug's primary indications include reduction of risk for stroke and systemic embolism in patients with non-valvular atrial fibrillation, treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prophylaxis after surgeries.
Market Size and Penetration
Current Market Environment
- The global anticoagulant market was valued at approximately USD 14.2 billion in 2022.[1]
- The segment specific to rivaroxaban (Xarelto) alone accounted for roughly USD 6 billion of this market in 2022.
- Rivarly in this space includes drugs such as apixaban (Eliquis), dabigatran (Pradaxa), and edoxaban (Savaysa).
Sales Volume
- Estimated US prescriptions for rivaroxaban reached 17 million in 2022.[2]
- Market share for rivaroxaban stands at about 58% in the oral anticoagulant segment.[3]
Competitive Dynamics
- Shift towards direct oral anticoagulants (DOACs) like rivaroxaban continues, driven by ease of use and comparable efficacy to warfarin.
- Generic competition exists for rivaroxaban, primarily in markets outside the US; U.S. patent exclusivity is expected to expire around 2024-2025.
Regulatory Status and Pricing Trends
Current Pricing
| Region |
Approximate Price per 30-day supply |
Source |
| US |
USD 560 |
[4] |
| EU |
EUR 480 |
[5] |
Pricing in the US shows stability due to patent protections. Once patents expire, generic versions are projected to reduce prices by up to 80%.[6]
Patent and Exclusivity Timeline
- The primary patent for Xarelto in the US expires in 2024.
- Patent protections in other major markets such as Europe and Japan are slated to expire in 2025-2026.
- Patent litigation and delays could extend exclusivity.
Price Projection Outlook
Near-term (2023-2024)
- US prices are expected to remain stable as patent protection continues.
- Limited impact from generics due to patent enforcement.
- Market expansion driven by new indications and increased adoption in emerging markets.
Mid-term (2025-2027)
- Introduction of generics in the US expected post-patent expiry.
- Price points could fall to USD 100–150 per 30-day supply.
- Anticipated market share spread among generic manufacturers may challenge current branded revenue by up to 70-80%.
Long-term (2028+)
- The market could stabilize with generic sales constituting 70-80% of volumes.
- Price erosion will plateau at 80-85% below current branded prices.
- Market growth may rely on increased use in emerging economies and new clinical data supporting expanded indications.
Strategic Market Opportunities
- Expansion into hospital and specialty pharmacy channels.
- Development of combination therapies targeting coagulation disorders.
- Expansion into markets with emerging healthcare infrastructure, notably Asia-Pacific and Latin America.
Risks and Challenges
- Patent litigation could delay generic entry.
- Shifts in clinical guidelines favoring alternative anticoagulants.
- Pricing pressures from healthcare systems seeking cost reductions.
- Competitive launches of next-generation anticoagulants with improved safety profiles.
Key Takeaways
- The current market for rivaroxaban is stable with high saturation in developed markets.
- Patents expire within the next 2 years, presaging significant price reductions.
- US prices are around USD 560/month; post-patent prices could fall to USD 100–150/month.
- Generics will dominate volume, but branded sales may persist in non-generic markets.
- Growth opportunities include new indications and emerging markets, offset by patent and competitive risks.
Frequently Asked Questions
Q1: When will generic rivaroxaban enter the US market?
A: Likely in late 2024 or early 2025, contingent upon patent litigation outcomes.
Q2: How much can prices drop after patent expiry?
A: Historically, prices decrease by 80% or more; for rivaroxaban, current USD 560 could fall to USD 100–150.
Q3: What are the main competitors for rivaroxaban?
A: Apixaban (Eliquis), dabigatran (Pradaxa), and edoxaban (Savaysa).
Q4: Are there new formulations or indications in the pipeline?
A: Clinical trials are ongoing for expanded uses; additional formulations are not currently planned.
Q5: How will emerging markets affect the market for rivaroxaban?
A: These markets will see increased adoption due to expanding healthcare infrastructure and cost-sensitive pricing post-generic entry.
References
[1] Market Research Future. (2023). Global Anticoagulants Market Report.
[2] IQVIA. (2022). Prescription Data for Oral Anticoagulants.
[3] EvaluatePharma. (2023). Market Share Data for DOACs.
[4] GoodRx. (2023). Rivaroxaban Pricing Analysis.
[5] European Medicines Agency. (2022). Pricing and Reimbursement Report.
[6] IMS Health. (2022). Generic Drug Price Trends.
